Alemtuzumab-CHOP chemotherapy has become experimental trial therapy for aggressive T cell lymphoma. Several multicenter phase III trials will incorporate this scheme. As part of an ongoing phase II trial in which we recently treated 20 patients with 8 cycles of CHOP every 2 weeks with 3 additional gifts of 30 mg alemtuzumab per cycle, we observed the development of EBV + lymphoproliferative disease, after completion of the immunochemotherapy in three patients with peripheral T cell lymphoma. As the occurrence of EBV + lymphoproliferative disease is rare after alemtuzumab monotherapy, such as is given for chronic lymphocytic leukaemia, we feel that early reporting of this potential side effect is warranted. It may be caused by intrinsic T cell defects in patients with T cell lymphoma, or by the combination of alemtuzumab with CHOP chemotherapy.
Introduction
The poor prognosis of peripheral T-cell lymphoma has generated new trials with immunochemotherapy consisting of the anti-CD52 monoclonal antibody alemtuzumab combined with CHOP (cyclophosphamide, adriamycin, oncovin, prednisone) chemotherapy. 1 Although increased infection rates have been reported in these alemtuzumab-CHOP trials, toxicity thus far has been manageable. 2 Based on these preliminary data, two alemtuzumab-based phase III trials and MgCl 2 incubation. Clonality of the EBV episomes was not investigated.
B-cell and T-cell clonality assessment:
Immunoglobulin-and T-cell receptor clonality analysis was performed on DNA extracted from paraffin-embedded tissue by multiplex IgH and TCR beta and gamma PCR according to the BIOMED-2 protocol. 3 The PCR products were detected by heteroduplex analysis or GeneScanning (TCR beta and gamma analysis courtesy of Prof. J.J. van Dongen, Erasmus Medical Center, Rotterdam).
Discussion
EBV-lymphoproliferative disease is a familiar complication after organ transplantation and related to the severity of immunosuppression 4, 5 . Most cases are of B-cell type, but T-cell EBVlymphoproliferative disease can also occur 6 . A comparable lymphoproliferative disorder may occur in the context of autoimmune disorders treated with immunosuppressive or immunomodulating agents. Here we report the occurrence of EBV-lymphoproliferative disease after strong suppressive immunochemotherapy consisting of alemtuzumab-CHOP for peripheral T-cell lymphoma.
Alemtuzumab (Campath-1H) targets CD52 that is present on virtually all B-and Tlymphocytes, monocytes and NK-cells, and is therefore highly immunosuppressive. Particularly the prolonged T-cell deficiency can lead to opportunistic infections 7;8 . Alemtuzumab has been widely used in patients with chronic lymphocytic leukemia (CLL) 9 , T-cell prolymphocytic leukemia (PLL) [10] [11] [12] , and more recently T-cell lymphoma 1;2;12-14 .
For
Despite the large numbers of patients with CLL or T-PLL treated, the occurrence of EBV lymphoproliferative disease after therapy with alemtuzumab seems very rare [15] [16] [17] . A patient with refractory Sézary syndrome, treated with alemtuzumab, who developed fatal adenoviral and enteroviral infections and EBV-positive large B-cell lymphoma was recently published 18 .
The fact that we observed several cases with EBV-lymphoproliferative disease after the completion of alemtuzumab-CHOP therapy for T-cell lymphoma is remarkable. Case 3 suffered from AILT, which is more often accompanied by secondary EBV + B-cell transformations 19;20 , however, both other cases had non-AILT T-cell lymphoma. Our observation suggest a relationship between this complication, the alemtuzumab-CHOP regimen, and T-cell lymphoma.
A relationship between EBV + B-cell lymphoma and T-cell lymphoma has been described, not only in AILT, but also in peripheral T-cell lymphoma 21 . Out of 600 cases with nodal T-cell lymphoma, 17 cases with secondary EBV-associated B-cell lymphoma were reported; 13 with AILT, one peripheral T-cell lymphoma, and three cases with co-existing EBV-related B-NHL as part of a composite lymphoma. These published cases were all treated before alemtuzumab became part of the therapy. The HOVON 69 alemtuzumab-CHOP scheme contained a very intensive alemtuzumab dose (90 mg per CHOP-14 cycle) compared with other trials in T-cell lymphoma. Within the forthcoming ACT1 and ACT2 trials, Alemtuzumab-CHOP-14, be it with less alemtuzumab (60 mg per CHOP-14 cycle) will be the experimental therapy for patients with peripheral T-NHL. It needs to be seen whether we will more often encounter EBV-driven B-cell and/or T-cell lymphomas if alemtuzumab-CHOP becomes standard therapy for patients with Tcell lymphoma. Although the poor outcome of T-cell lymphoma justifies high-risk therapy modalities, awareness of this complication is important. In addition, EBV-DNA monitoring could lead to early detection. However, whether early treatment, e.g. anti-CD20 monoclonal antibody in case of a secondary EBV+ B-cell lymphoma, will be effective after alemtuzumab-CHOP, remains to be determined. 
